Introduction. Increased blood pressure is one of discriminant criteria for presence of metabolic syndrome (MS). Despite of numerous analyses of antihypertensive therapy, its evaluation in association to MS are seldom.
Method: Crosssectional multicentric screening of MS and structure of medication was performed in 8679 consequetive out-ward patients in whole territory of Slovakia. MS
was defined according to IDF criteria (IDF 2005).
Results. Out-ward patients aged 52.4±16.1 yrs [17-96 yrs] exhibited 25.6% prevalence of MS (23.7% in males; 26.9% in females; p<0.01). Hypertension (BP≥140/90 mmHg) or antihypertensive therapy were present in 65.8% pts. Target blood pressure for MS [BP <130/85 mm Hg] was reached in 13.3% of MS+ pts and 14.7% of MS- of treated hypertensive patients (NS). MS + pts were more often unsuccessfully treated (70.1% vs. 54.4%; p<0.001). Both subgroups had similar structure of therapy, however, MS+ pts were treated more expensively – antihypertensive therapy was 14.9 vs 13.1 SK of DDD (p<0.001); hypolipodemic therapy was 12.3 vs 10.7 SK of DDD (p<0.001); and whole therapy was 34.7 vs 30.3 SK of DDD (p<0.01).
Conclusion: Project NEMESYS found 25.6% prevalence of metabolic syndrom between out-ward patients. Their antihypertensive and hypolipidemic therapies were more expensive and equally efficient (resp. non.efficient) in comparison with patients without MS. Only 14% of pts reached normotension.